More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng\/mL<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 14, 2023 (HealthDay News) — For patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer, alectinib exposure is lower when taken with low-fat yogurt, according to a study published in the June issue of the Journal of the National Comprehensive Cancer Network<\/em>.<\/p>\n Daan A.C. Lanser, from Erasmus MC Cancer Institute in Rotterdam, Netherlands, and colleagues conducted a randomized three-period crossover clinical study comparing alectinib exposure among patients with different diets. The first alectinib dose was taken with a continental breakfast, 250-g low-fat yogurt, or a self-chosen lunch every seven days, and the second dose was taken with a self-chosen dinner. On day 8, sampling for alectinib exposure (Ctrough<\/sub>) was performed, just prior to alectinib intake.<\/p>\n The researchers found that the mean Ctrough <\/sub>was 14 and 20 percent lower when taken with low-fat yogurt compared with continental breakfast and self-chosen lunch, respectively, in 20 evaluable patients. Exposure did not change for administration with a self-chosen lunch compared with a continental breakfast. <\/p>\n “This is important information for patients, since we know that higher alectinib concentrations in blood could result in more efficacy of the drug, a longer treatment duration and therefore, hopefully, a better survival,” Lanser said in a statement. “We believe that taking it with a substantial meal containing enough fat is far more important for the absorption and efficacy of the treatment than to wait 12 hours between doses.”<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n